B-intervention	0	8	Elevated
I-intervention	9	15	plasma
I-intervention	16	22	tissue
I-intervention	23	32	inhibitor
I-intervention	33	35	of
I-intervention	36	53	metalloproteinase
I-intervention	53	54	-
I-intervention	54	55	1
O	56	61	level
O	62	70	predicts
O	71	80	decreased
O	81	89	response
O	90	93	and
O	94	102	survival
O	103	105	in
O	106	116	metastatic
O	117	123	breast
O	124	130	cancer
O	130	131	.

O	132	138	Tissue
O	139	149	inhibitors
O	150	152	of
O	153	170	metalloproteinase
O	171	172	(
O	172	177	TIMPs
O	177	178	)
O	179	183	have
O	184	186	at
O	187	192	least
O	193	194	2
O	195	204	different
O	205	214	functions
O	214	215	.

O	216	220	They
O	221	228	inhibit
O	229	232	the
O	233	242	catalytic
O	243	251	activity
O	252	254	of
O	255	261	matrix
O	262	280	metalloproteinases
O	280	281	,
O	282	285	and
O	286	290	they
O	291	294	act
O	295	297	as
O	298	304	growth
O	305	312	factors
O	312	313	.

O	314	326	Pretreatment
O	327	342	ethylenediamine
O	343	353	tetracetic
O	354	358	acid
O	359	365	plasma
O	366	370	TIMP
O	370	371	-
O	371	372	1
O	373	376	was
O	377	384	assayed
O	385	389	from
B-intervention-participants	390	393	251
O	394	402	patients
O	403	406	who
O	407	411	were
O	412	420	enrolled
O	421	423	in
O	424	425	a
O	426	431	Phase
O	432	435	III
O	435	436	,
O	437	443	second
O	443	444	-
O	444	448	line
O	448	449	,
O	450	457	hormone
O	458	465	therapy
O	466	471	trial
O	471	472	,
O	473	476	and
O	477	481	from
O	482	483	a
B-control	484	491	control
I-control	492	497	group
O	498	500	of
B-control-participants	501	503	50
O	504	511	healthy
O	511	512	,
O	513	527	postmenopausal
O	528	533	women
O	534	536	by
O	537	542	using
O	543	546	the
O	547	551	TIMP
O	551	552	-
O	552	553	1
O	554	560	enzyme
O	560	561	-
O	561	567	linked
O	568	581	immunosorbent
O	582	587	assay
O	587	588	.

O	589	592	The
O	593	599	plasma
O	600	604	TIMP
O	604	605	-
O	605	606	1
O	607	613	levels
O	614	618	from
O	619	622	the
O	623	637	postmenopausal
O	638	645	control
O	646	651	group
O	652	653	(
O	653	654	n
O	655	656	=
O	657	659	50
O	660	665	women
O	665	666	)
O	667	671	were
O	672	675	201
O	676	677	+
O	677	678	/
O	678	679	-
O	680	682	86
O	683	685	ng
O	685	686	/
O	686	688	mL
O	689	693	mean
O	694	695	+
O	695	696	/
O	696	697	-
O	698	706	standard
O	707	716	deviation
O	717	718	(
O	718	723	range
O	723	724	,
O	725	727	49
O	727	728	-
O	728	731	455
O	732	734	ng
O	734	735	/
O	735	737	mL
O	737	738	)
O	738	739	.

O	740	743	The
O	744	749	upper
O	750	755	limit
O	756	758	of
O	759	765	normal
O	766	769	was
O	770	777	defined
O	778	780	as
O	781	784	the
O	785	789	mean
O	790	791	+
O	791	792	/
O	792	793	-
O	794	795	2
O	796	804	standard
O	805	815	deviations
O	816	818	of
O	819	822	the
O	823	830	control
O	831	836	group
O	837	838	(
O	838	841	373
O	842	844	ng
O	844	845	/
O	845	847	mL
O	847	848	)
O	848	849	.

O	850	857	Patient
O	858	870	pretreatment
O	871	877	plasma
O	878	882	TIMP
O	882	883	-
O	883	884	1
O	885	891	levels
O	892	898	ranged
O	899	903	from
O	904	906	70
O	907	909	ng
O	909	910	/
O	910	912	mL
O	913	915	to
O	916	919	982
O	920	922	ng
O	922	923	/
O	923	925	mL
O	925	926	.

B-outcome	927	933	Plasma
I-outcome	934	938	TIMP
I-outcome	938	939	-
I-outcome	939	940	1
O	941	944	was
O	945	953	elevated
O	954	959	above
O	960	963	the
O	964	968	mean
O	969	970	+
O	971	972	2
O	973	981	standard
O	982	992	deviations
O	993	995	of
O	996	999	the
O	1000	1007	control
O	1008	1013	group
O	1014	1015	(
B-iv-cont-mean	1015	1018	373
I-iv-cont-mean	1019	1021	ng
I-iv-cont-mean	1021	1022	/
I-iv-cont-mean	1022	1024	mL
O	1024	1025	)
O	1026	1028	in
B-cv-bin-abs	1029	1031	19
O	1032	1040	patients
O	1041	1042	(
B-cv-bin-percent	1042	1043	7
I-cv-bin-percent	1043	1044	.
I-cv-bin-percent	1044	1045	6
I-cv-bin-percent	1045	1046	%
O	1046	1047	)
O	1047	1048	.

O	1049	1051	In
O	1052	1062	univariate
O	1063	1071	analysis
O	1071	1072	,
O	1073	1081	patients
O	1082	1085	who
O	1086	1089	had
O	1090	1098	elevated
O	1099	1105	versus
O	1106	1112	normal
O	1113	1119	plasma
O	1120	1124	TIMP
O	1124	1125	-
O	1125	1126	1
O	1127	1133	levels
O	1134	1137	had
O	1138	1139	a
O	1140	1147	reduced
B-outcome	1148	1156	clinical
I-outcome	1157	1164	benefit
I-outcome	1165	1169	rate
O	1170	1171	(
O	1171	1174	CBR
O	1174	1175	)
O	1176	1177	(
B-iv-bin-percent	1177	1179	16
I-iv-bin-percent	1179	1180	%
O	1181	1183	vs
B-cv-bin-percent	1184	1186	42
I-cv-bin-percent	1186	1187	%
O	1187	1188	;
O	1189	1190	P
O	1191	1192	=
O	1193	1194	.
O	1194	1196	03
O	1196	1197	)
O	1197	1198	.

O	1199	1202	The
B-outcome	1203	1207	time
I-outcome	1208	1210	to
I-outcome	1211	1222	progression
I-outcome	1223	1224	(
I-outcome	1224	1227	TTP
I-outcome	1227	1228	)
O	1229	1230	(
B-iv-cont-median	1230	1232	84
I-iv-cont-median	1233	1237	days
O	1238	1240	vs
B-cv-cont-median	1241	1244	174
I-cv-cont-median	1245	1249	days
O	1249	1250	;
O	1251	1252	P
O	1253	1254	<
O	1255	1256	.
O	1256	1260	0001
O	1260	1261	)
O	1262	1265	and
B-outcome	1266	1273	overall
I-outcome	1274	1282	survival
O	1283	1284	(
B-iv-cont-median	1284	1287	141
I-iv-cont-median	1288	1292	days
O	1293	1295	vs
B-cv-cont-median	1296	1299	860
I-cv-cont-median	1300	1304	days
O	1304	1305	;
O	1306	1307	P
O	1308	1309	=
O	1310	1311	.
O	1311	1315	0001
O	1315	1316	)
O	1317	1321	also
O	1322	1326	were
O	1327	1340	significantly
O	1341	1348	shorter
O	1349	1351	in
O	1352	1360	patients
O	1361	1364	who
O	1365	1368	had
O	1369	1377	elevated
O	1378	1382	TIMP
O	1382	1383	-
O	1383	1384	1
O	1385	1391	levels
O	1391	1392	.

B-outcome	1393	1396	TTP
I-outcome	1397	1400	and
I-outcome	1401	1408	overall
I-outcome	1409	1417	survival
O	1418	1422	also
O	1423	1427	were
O	1428	1441	significantly
O	1442	1449	shorter
O	1450	1452	in
O	1453	1461	patients
O	1462	1465	who
O	1466	1469	had
O	1470	1476	higher
O	1477	1481	TIMP
O	1481	1482	-
O	1482	1483	1
O	1484	1490	plasma
O	1491	1497	levels
O	1498	1502	when
O	1503	1505	it
O	1506	1509	was
O	1510	1518	analyzed
O	1519	1521	as
O	1522	1523	a
O	1524	1534	continuous
O	1535	1543	variable
O	1543	1544	.

O	1545	1547	In
O	1548	1560	multivariate
O	1561	1569	analysis
O	1569	1570	,
O	1571	1579	elevated
O	1580	1586	plasma
O	1587	1591	TIMP
O	1591	1592	-
O	1592	1593	1
O	1594	1599	level
O	1600	1608	remained
O	1609	1610	a
O	1611	1621	prognostic
O	1622	1628	factor
O	1629	1632	for
O	1633	1640	reduced
O	1641	1648	overall
O	1649	1657	survival
O	1658	1659	(
O	1659	1660	P
O	1661	1662	<
O	1663	1664	.
O	1664	1668	0001
O	1668	1669	)
O	1670	1675	along
O	1676	1680	with
O	1681	1689	elevated
O	1690	1695	serum
O	1696	1699	HER
O	1699	1700	-
O	1700	1701	2
O	1701	1702	/
O	1702	1705	neu
O	1706	1707	(
O	1707	1708	P
O	1709	1710	<
O	1711	1712	.
O	1712	1716	0001
O	1716	1717	)
O	1718	1721	and
O	1722	1725	the
O	1726	1734	presence
O	1735	1737	of
O	1738	1746	visceral
O	1747	1757	metastases
O	1758	1759	(
O	1759	1760	P
O	1761	1762	=
O	1763	1764	.
O	1764	1767	008
O	1767	1768	)
O	1768	1769	.

O	1770	1778	Elevated
O	1779	1791	pretreatment
O	1792	1798	plasma
O	1799	1805	levels
O	1806	1808	of
O	1809	1813	TIMP
O	1813	1814	-
O	1814	1815	1
O	1816	1825	predicted
O	1826	1827	a
O	1828	1837	decreased
O	1838	1846	response
O	1847	1849	to
O	1850	1856	second
O	1856	1857	-
O	1857	1861	line
O	1862	1869	hormone
O	1870	1877	therapy
O	1878	1881	and
O	1882	1889	reduced
O	1890	1898	survival
O	1899	1901	in
O	1902	1907	women
O	1908	1912	with
O	1913	1923	metastatic
O	1924	1930	breast
O	1931	1937	cancer
O	1937	1938	.
